L3VLUP
ProSign in

OCUL in the 13F filings

Ocular Therapeutix Inc · CUSIP 67576A100

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q1 2023Q3 2021
Quarter end
31 Mar 2024
the date the book describes
Filed
15 May 2024
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2023 and Q1 2024; 0 listed it in both
Shares listed
1,086,794
combined, among listed positions
Reported value
$9.9m
combined, at the quarter end

Among the 93 comparable managers: 1 buyer (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,086,794.

Managers listing OCUL in Q1 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Voloridge Investment Management LLC1,086,794$9.9munder 0.1%Newnew15 May 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

024620152016201720212023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
OCUL by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20141$14mn.a.n.a.
Q4 20141$22mn.a.n.a.
Q1 20152$121mn.a.n.a.
Q2 20153$107mn.a.n.a.
Q3 20153$72mn.a.n.a.
Q4 20152$46mn.a.n.a.
Q1 20162$47mn.a.n.a.
Q2 20161$97kn.a.n.a.
Q3 20161$143kn.a.n.a.
Q4 20161$1.9mn.a.n.a.
Q1 20171$1.6mn.a.n.a.
Q2 20201$289kn.a.n.a.
Q4 20202$41mn.a.n.a.
Q1 20212$39mn.a.n.a.
Q2 20211$17mn.a.n.a.
Q3 20211$11mn.a.n.a.
Q1 20231$344kn.a.n.a.
Q1 20241$9.9m10
Q2 20241$19m10
Q3 20243$36m21
Q4 20243$45m30
Q1 20252$14m02
Q2 20251$9.9m01
Q3 20253$86m30
Q4 20255$88m2211
Q1 20264$69m1913
Q2 20261$16m1020

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

OCUL and LLY →OCUL and JNJ →OCUL and VRTX →Choose a stock to compare with OCUL →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own OCUL, latest filings →Back to the 13F Explorer →